TISSIUM is a privately-owned medical technology company founded in 2013 and developing biomorphic programmable polymers for atraumatic tissue repair and reconstruction. It is headquartered in Paris, with a production facility in Roncq (near Lille) and an office in Boston.
Currently, the company has a pipeline of products across three verticals, including peripheral nerve repair, hernia repair, and cardiovascular sealing.
The company's technology is the result of research and intellectual property from the laboratories of Professor Robert Langer (MIT) and Professor Jeffrey M. Karp (Brigham and Women's Hospital) developed by the company’s co-founder and Chief Innovation Officer Maria Pereira. Christophe Bancel, co-founder, and CEO of TISSIUM, has led the charge since inception, directing the company as it has conducted R&D, various clinical trials, and fundraising efforts resulting in €170 million in funding for the company.